Drug Trial Radar · NCT06938321
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
135
Planned (sponsor's estimate)
Start
Apr 30, 2025
Primary completion
May 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Apr 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
There're 2 parts in this interventional study: 1. The goal of phase Ib trial is to evaluate the safety and tolerability of AK130 in combination with AK112 therapy for the purpose of observing the incidence of dose limit toxicity (DLT) as well as the confirmation of maximum tolerable dose (MTD) in the treatment of advanced biliary tract cancer (BTC), so as to determine the recommended phase 2 dose (RP2D) in the second part of the trial. 2. The goal of phase II trial is to evaluate the safety and efficacy of AK112 in combination with AK130 therapy or monotherapy in the treatment of advanced BTC.
Conditions
- Biliary Tract Cancer
Interventions
AK112Drug
Following a predefined dose and date.
AK130Drug
Following a predefined dose and date.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with dose limiting toxicities (DLTs)Time frame: During the first three weeks.
- Number of subjects with adverse events (AEs)Time frame: From the time of informed consent signed through 30 days after the last dose of study drug or starting new anti-cancer therapy.
- Objective Response Rate (ORR) (Phase II)Time frame: Through study completion, an average of 2 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.